MeiraGTx (NASDAQ:MGTX) & Ascendis Pharma A/S (NASDAQ:ASND) Financial Contrast

MeiraGTx (NASDAQ:MGTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.

Valuation and Earnings

This table compares MeiraGTx and Ascendis Pharma A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39 million	16.39	-$114.20 million	$0.71	19.56
Ascendis Pharma A/S	$814.57 million	20.72	-$258.00 million	$12.89	20.99

MeiraGTx has higher earnings, but lower revenue than Ascendis Pharma A/S. MeiraGTx is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MeiraGTx and Ascendis Pharma A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1	0	5	2	3.00
Ascendis Pharma A/S	0	1	17	2	3.05

MeiraGTx presently has a consensus price target of $26.17, indicating a potential upside of 88.38%. Ascendis Pharma A/S has a consensus price target of $310.05, indicating a potential upside of 14.60%. Given MeiraGTx’s higher probable upside, equities analysts clearly believe MeiraGTx is more favorable than Ascendis Pharma A/S.

Risk & Volatility

MeiraGTx has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Insider & Institutional Ownership

67.5% of MeiraGTx shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares MeiraGTx and Ascendis Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Summary

Ascendis Pharma A/S beats MeiraGTx on 8 of the 14 factors compared between the two stocks.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.